At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 77 enrolled
Drug / intervention
CMVpp65 Specific T-cellsbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation
In Brief
A Phase 2 clinical trial evaluating CMVpp65 Specific T-cells for CMV Infection and Persistent CMV Viremia. Completed, enrolled 77 participants across 1 site.
Detailed Summary
The purpose of this study is to see how well transfusions of T-cells work in treating CMV. Tcells are a type of white blood cell that helps protect the body from infection. A transfusion is the process by which blood from one person is transferred to the blood of another. In this case, the T-cells are made from the blood of donors who are immune to CMV. The T-cells are then grown and taught to attack the CMV virus in a lab.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCMV Infection, Persistent CMV Viremia
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartMay 2014
First PostedMay 2014
Primary CompletionFeb 2024
TodayJul 2026
First PostedMay 13, 2014
Enrollment StartMay 8, 2014
Primary CompletionFeb 8, 2024
TodayJul 2, 2026
Enrollment to primary: 9.8 yearsPosted 12.1 years ago
Interventions
CMVpp65 Specific T-cellsbiological